The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease

被引：0
|
作者：
Neasa Mc Gettigan
Aman Shah Afridi
Grace Harkin
Caroline Lardner
Stephen Patchett
Danny Cheriyan
Gavin Harewood
Karen Boland
Aoibhlinn O’Toole
机构：
[1] Beaumont Hospital,
来源：
International Journal of Colorectal Disease | 2021年 / 36卷
关键词：
Biologics; Ulcerative colitis; Crohn’s disease; Immunogenicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1231 / 1241
页数：10
相关论文
共 50 条
  • [1] The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
    Mc Gettigan, Neasa
    Afridi, Aman Shah
    Harkin, Grace
    Lardner, Caroline
    Patchett, Stephen
    Cheriyan, Danny
    Harewood, Gavin
    Boland, Karen
    O'Toole, Aoibhlinn
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (06) : 1231 - 1241
  • [2] Anti-drug antibodies to infliximab: A comparison of free anti-drug antibody measurement
    Hamilton, R.
    Shields, S.
    MacDonald, J.
    Dunlop, A.
    Perry, M.
    McGucken, A.
    Gribben, E.
    Galloway, P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S249 - S250
  • [3] ANTI-DRUG ANTIBODIES TO INFLIXIMAB: A COMPARISON OF FREE ANTI-DRUG ANTIBODY MEASUREMENT
    Hamilton, Rhona
    Shields, Stephanie
    Macdonald, Jonathan
    Dunlop, Allan
    Perry, Martin
    McGucken, Andrew
    Gribben, Elain
    Galloway, Peter
    [J]. GUT, 2021, 70 : A121 - A121
  • [4] Importance of Determining Anti-drug Antibodies in the Treatment of inflammatory Bowel Disease with Infliximab
    Langmann, Anna
    Langmann, Peter
    [J]. INTERNIST, 2019, 60 : S8 - S8
  • [5] Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease
    Lopez-Ibanez, Maria
    Marin-Jimenez, Ignacio
    [J]. GASTROENTEROLOGIA Y HEPATOLOGIA, 2016, 39 (04): : 265 - 272
  • [6] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A. S.
    van den Brink, G. R.
    Ponsioen, C.
    Mathot, R.
    Loewenberg, M.
    D'Haens, G. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
  • [7] Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease
    Ha, Christina
    Mathur, Jagrati
    Kornbluth, Asher
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (04) : 497 - 505
  • [8] Management of Anti-drug Antibodies to Biologic Medications in Children With Inflammatory Bowel Disease
    Cohen, Reuven Zev
    Schoen, Bess T.
    Kugathasan, Subra
    Sauer, Cary G.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2019, 69 (05): : 551 - 556
  • [9] Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A.
    van den Brink, G.
    Ponsioen, C.
    Mathot, R.
    Lowenberg, M.
    D'Haens, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S69 - S70
  • [10] LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY FORMATION TO THE PRIOR ANTI-TNF PREDISPOSES PATIENTS WITH INFLAMMATORY BOWEL DISEASE TO DEVELOP ANTI-DRUG ANTIBODIES TO THE SUBSEQUENT ANTI-TNF
    Cheifetz, Adam S.
    Abreu, Maria T.
    Flier, Sarah N.
    Papamichail, Konstantinos
    Rieder, Florian
    Silverberg, Mark S.
    Khanna, Reena
    Okada, Lauren
    Yang, Lei
    Jain, Anjali
    Vande Casteele, Niels
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S457 - S457
12345